Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model

Free Radical Biology and Medicine

Volumn 26, Issue 11-12, 1999, Pages 1538-1543

  Gozzo, Andrea ^a   Lesieur, Daniel ^a   Duriez, Patrick ^b   Fruchart, Jean Charles ^b   Teissier, Elisabeth ^b  

^a Universite de Lille   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Antioxidant; Free radicals; Lipid; Low density lipoprotein; Melatonin; Peroxidation; Structure activity relationship

Indexed keywords

2 (5 HYDROXYINDOL 3 YL)ETHYLAMINE; 2 (5 METHOXYINDOL 3 YL)ETHYLAMINE 5 METHOXYTRYPTAMINE; 2 (6 METHOXYINDOL 3 YL)ETHYLAMINE 6 METHOXYTRYPTAMINE; 2 (INDOL 3 YL)ETHYLAMINE TRYPTAMINE; FREE RADICAL; MELATONIN; MELATONIN DERIVATIVE; N [2 (5 HYDROXYINDOL 3 YL)ETHYL]ACETAMIDE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN EXPERIMENT; LIPID PEROXIDATION; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0033027481     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00020-9     Document Type: Article

References (33)

1. Delagrange P., Guardiola-Lemaitre B. Melatonin, its receptors, and relationships with biological rhythm disorders. Clin. Neuropharmacol. 20:1997;482-510.
2. Maestroni G.J.M. The immunoneuroendocrine role of melatonin. J. Pineal Res. 14:1993;1-10.
3. Guardiola-Lemaitre B., Lenégre A., Porselt R.D. Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse. Pharmacol. Biochem. Behav. 41:1992;405-408.
4. Therapeutic potential of melatonin. Maestroni, G. J. M.; Conti, A.; Reiter, R. J. , eds Karger, Basel (1997).
5. Nowak J.Z., Zawilska J.B. Melatonin and its physiological and therapeutic properties. Pharm. World Sci. 20:1998;18-27.
6. Marshall K.-A., Reiter R.J., Poeggeler B., Aruoma O.I., Halliwell B. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic. Biol. Med. 21:1996;307-315.
7. Abuja P.M., Liebmann P., Hayn M., Schauenstein K., Erstebauer H. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Letters. 413:1997;289-293.
8. Chan T.-Y., Tang P.-L. Characterization of the antioxidant effects of melatonin and related indoleamines in vitro. J. Pineal Res. 20:1996;187-191.
9. Tan D.X., Chen L.D., Poeggeler B., Manchester L.D., Reiter R.J. Melatonin A potent, endogenous hydroxyl radical scavenger . Endocrine J. 1:1993;57-60.
10. Matuszak Z., Reszka K.J., Chignell C.F. Reaction of melatonin and related indoles with hydroxyl radicals EPR and spin trapping investigations . Free Radic. Biol. Med. 23:1997;367-372.
11. Pieri C., Marra M., Moroni F., Recchioni R., Marcheselli F. Melatonin a peroxyl radical scavenger more effective than vitamin E . Life Sci. 55:1994;271-276.
12. Tan D.X., Poeggeler B., Reiter R.J., Chen L.D., Manchester L.D., Barlow-Walden L.R. The pineal hormone melatonin inhibits DNA adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 70:1993;65-71.
13. Tan D.X., Reiter R.J., Chen L.D., Poeggeler B., Manchester L.D., Barlow-Walden L.R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis. 15:1994;215-218.
14. Melchiorri D., Reiter R.J., Attia A.M., Hara M., Burgos A., Nistico G. Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci. 56:1995;83-85.
15. Pierrefiche G., Topall G., Cauboin G., Henriet I., Laborit H. Antioxidant activity of melatonin in mice. Res. Commun. Chem. Pathol. Pharmacol. 80:1993;211-223.
16. Vijayalaxmi; Reiter, R. J.; Sewerynek, E.; Poeggeler, B.; Leal, B. Z.; Meltz, M. L. Marked reduction of radiation-induced micronuclei in human blood lymphocytes pretreated with melatonin. Radiation Res. 143:102-106; 1995.
17. Steinberg D., Parthasarthy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond Cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
18. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witzum J.J., Steinberg D. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095.
19. Aviram M. Modified forms of low-density lipoprotein and atherosclerosis. Atherosclerosis. 98:1993;1-9.
20. Pieri C., Marra M., Gaspar R., Damjanovich S. Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Biochem. Bioph. Res. Comm. 222:1996;256-260.
21. Kelly M.R., Loo G. Melatonin inhibits oxidative modification of human low-density lipoprotein. J. Pineal Res. 22:1997;203-209.
22. Seeger H., Mueck A.O., Lippert T.H. Effect of melatonin on copper-mediated oxidation of low-density lipoprotein. Br. J. Clin. Pharmacol. 44:1997;283-284.
23. Longoni B., Salgo G.M., Pryor W.A., Marchiafava P.L. Effects of melatonin on lipid peroxidation induced by oxygen radicals. Life Sci. 62:1988;853-859.
24. Walters-Laporte E., Furman C., Fouquet S., Martin-Nizard F., Lestavel S., Gozzo A., Lesieur D., Fruchart J.C., Duriez P., Teissier E. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized-LDL toxicity towards cultured endothelial cells. J. Cardiovasc. Pharmacol. 32:1998;582-592.
25. Poggeler B., Saarela S., Reiter R.J., Tan D.-X., Chen L.-D., Manchester L.C., Barlow-Walden L.R. Melatonin-a highly potent endogenous radical scavenger and electron donor new aspects of the oxidation chemistry of this indole accessed in vitro . Ann. N. Y. Acad. Sci. 738:1994;419-420.
26. Migliavacca E., Ancerewicz J., Carrupt P.-A., Tetsa B. Theoretical parameters to characterize antioxidants. Part 2. The case of melatonin and carvedilol. Helv. Chim. Acta. 81:1998;1337-1348.
27. Turjanski A.G., Rosenstein R.E., Estrin D.A. Reactions of melatonin and related indoles with free radicals a computational study . J. Med. Chem. 41:1998;3684-3689.
28. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1955;1345-1353.
29. Peterson G. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83:1977;346-356.
30. Esterbauer H., Striegl G., Puhl H., Rotheneder M. Continuos monitoring of in vitro oxidation of human low-density lipoprotein. Free Radic. Res. Comm. 6:1989;67-75.
31. Lissi E.A., Faure M., Montoya N., Videla L.A. Reactivity of indole derivatives towards oxygenated radicals. Free Radic. Res. Comm. 15:1991;211-222.
32. Brown D.W., Graupner P.R., Sainsbury M., Shertzer H.G. New antioxidants incorporating indole and indoline chromophores. Tetrahedron. 47:1991;4383-4408.
33. mt1 and MT2 receptor binding affinities performed by ADIR Company, data not published.